跳至主要内容
临床试验/NCT02193581
NCT02193581已完成不适用

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging: the MDS (Melanoma Detecting System)

Orlucent, Inc1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2017年8月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Orlucent, Inc
入组人数
50
试验地点
1
主要终点
The MDS produces a score between 1 to 10.

研究概览

简要总结

The use of MDS to access the presence of melanoma in the skin.

详细描述

A topical agent is applied to suspicious skin lesions and imaged. The images are analyzed to provide a score that correlates with the probability for the presence of melanoma in the lesion.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Individuals with skin lesion with one or more of the ABCDE features and recommended for a skin biopsy.
  • The lesion is accessible to the imaging device, with at least 1 cm of skin around the lesion that is accessible to the MDS.
  • Male and female ≥ 21 years old.
  • Subject is capable of giving written informed consent.
  • Primary excision.

排除标准

  • The lesion is less than 1 cm from the eyes.
  • The lesion is on the palms of hands or soles of the feet.
  • Mucosal lesion.
  • Pregnant females.
  • Low study procedure compliance.
  • Patients who are mentally or physically unable to comply with all aspects of the study.
  • Undergoing chemotherapy.
  • Minor or legally incompetent and not able to sign the consent form.
  • Patient previously tested by MDS and was diagnosed with melanoma during the study.
  • Sensitivity to fluorescein

结局指标

主要结局

The MDS produces a score between 1 to 10.

时间窗: 28 days

The score is a composite of the images of the mole, plus demographic and clinical information. The score is ranked from 1 to 10, with 1 being the lowest risk for melanoma, and 10 being the highest risk.

次要结局

未报告次要终点

研究者

发起方
Orlucent, Inc
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验